Life Sciences

Biopharma's $300 Billion Problem Is Driving the Biggest M&A Cycle in a Decade

More than $300 billion in branded pharmaceutical revenue faces patent expiration by 2030. Big Pharma cannot replace it through internal R&D alone. The result is the most aggressive acquisition cycle since before the pandemic, and it is reshaping how the entire life sciences supply chain does business.

Why Does Benchmark’s Work Need More Visibility

In an industry defined by rapid scientific breakthroughs, Benchmark Products plays a quietly pivotal role—translating innovation into tangible tools that life sciences manufacturers can actually use. By staying aligned with the evolving needs of patients and producers alike, Benchmark has built a reputation for agility, rapidly manufacturing solutions that improve efficiency and enable new…

Expanding Monitoring in Acute Care and Beyond

As hospitals look beyond the ICU to improve outcomes across the entire continuum of care, a key question emerges: how do you expand patient monitoring without overwhelming clinicians with more alarms, more noise, and more work? This episode—part three of a five-part Health and Life Sciences at the Edge series exploring The Future of…

AI-Driven Amino Acid Drugs Surface as a Promising Treatment for Eye Conditions

The rapid evolution of artificial intelligence (AI) promises to revolutionize multiple sectors, and one area seeing tangible benefits is drug development. Historically, the creation of new medicines was a time-consuming endeavor, but AI-driven amino acid research is proving to accelerate the early developmental stages and get drugs to the market faster. Researchers at the Wilmer…